Evaluation of 3D Magnetic Resonance Spirometry : Comparison to Spirometry in Healthy Subjects and Patients With Asthma and COPD (gb-Spiro3D)
Asthma, COPD
About this trial
This is an interventional other trial for Asthma focused on measuring Lung disease, Asthma, COPD, Spirometry, MRI, 3D MR Spirometry
Eligibility Criteria
Inclusion Criteria: Ability to understand the nature and objectives of the study and to appreciate the risks involved Ability to stand in an MRI machine without moving in supine and prone positions Informed and written consent For healthy subjects: No known diagnosed lung disease such as respiratory failure, COPD, asthma or cancer Non-smoker For asthmatic subjects: Asthma of varying degrees of severity Non-smoker For COPD subjects COPD with different degrees of severity Exclusion Criteria: Refusal to sign consent Any pathology or condition (active tumor, pregnancy, breastfeeding) that the investigators believe may compromise the safety of the subject or the objectives of the study Persons who have had a symptomatic Covid-19 infection Contraindication to performing an MRI examination (claustrophobia, metallic prosthesis, pacemaker, metallic prosthetic heart valve, cochlear implants, vascular clips, insulin pump) Contraindication to spirometry testing (acute myocardial infarction, severe systemic hypotension or hypertension, significant atrial/ventricular arrhythmia, uncompensated heart failure, uncontrolled pulmonary hypertension, pulmonary embolism, history of syncope, cerebral aneurysm, brain surgery (4 weeks), recent concussion, eye surgery (1 week), sinus or middle ear surgery, pneumothorax, thoracic or abdominal surgery (4 weeks) Contraindication to the administration of a short-acting bronchodilator (history of hypersensitivity to the active substance or to one of the excipients, history of intolerance to the product such as the occurrence of cough or bronchospasm after inhalation, pregnancy, thyrotoxicosis, coronary artery disease, hypertrophic obstructive cardiomyopathy, hypertension, tachyarrhythmia, diabetes, association with digitalis, MAO inhibitors, tricyclic antidepressants, known hypokalemia or hypokalemic drugs: diuretics, laxatives, steroids, xanthine). Non-membership in a social security system Protected persons (guardianship, curatorship) For healthy subjects and asthmatic subjects Tobacco history of more than 5 packs/year
Sites / Locations
- CEA | Service Hospitalier Fréderic Joliot
Arms of the Study
Arm 1
Other
Healthy volunteers, Asthmatic patients and COPD patients
This arm of the study is essential to establish nominal flow-volume maps of nominal flow-volume curves and to determine the dependence of normal breathing on gravity and response to a bronchodilator in order to evaluate the sensitivity and specificity of the technique for the known lung diseases asthma and COPD by comparing data from healthy the data from healthy subjects with those from sick subjects.